Endo Glucagon No Reconstitution Vs Reconstitution Severe Hypoglycemia

---
name: endo-glucagon-no-reconstitution-vs-reconstitution-severe-hypoglycemia
description: Recommends using glucagon preparations that do not require reconstitution (e.g., nasal, autoinjector) over those needing reconstitution for treating outpatient severe hypoglycemia to ensure prompt, correct dosing. Triggered when prescribing glucagon for type 1 or type 2 diabetes patients on insulin or sulfonylureas, counseling caregivers on rescue therapy, or following a severe hypoglycemia episode.
---

# Glucagon Preparations That Do Not Require Reconstitution vs Those That Do for Outpatient Severe Hypoglycemia

## STEP 1 — Gather Information
Collect patient diabetes type, insulin or sulfonylurea use, history of severe hypoglycemia, caregiver training status, and availability of glucagon formulations (nasal, autoinjector, or powder/diluent kit). If the patient has T1D or T2D on insulin/SU and is at risk for severe hypoglycemia, proceed to step 2.

## STEP 2 — Rule In / Rule Out
Determine if the patient is experiencing severe hypoglycemia (level 3) defined as altered mental status or physical inability to self‑treat with oral carbohydrates. If yes, proceed to step 3; if no, administer oral carbohydrates, monitor glucose, and reassess.

## STEP 3 — Classify or Stratify
Assess whether a non‑reconstituted glucagon preparation (nasal spray or autoinjector) is available and caregivers are trained to administer it. If yes, classify as prefer non‑reconstituted; if only the reconstituted powder/diluent kit is available, classify as need reconstituted kit.

## STEP 4 — Decide
If non‑reconstituted glucagon is available and caregivers trained, administer that formulation immediately per device instructions. If only the reconstituted kit is available, reconstitute according to label, administer intramuscularly, and prescribe a non‑reconstituted formulation for future use.

## Clinical Guardrails / Mimics / Pitfalls
Do not delay glucagon administration while reconstituting; do not use expired, discolored, or improperly stored glucagon; do not administer intramuscularly without proper training; do not rely solely on glucagon without calling emergency services if mental status does not improve; do not use nasal glucagon in patients with significant nasal obstruction or recent nasal surgery; ensure caregivers recognize severe hypoglycemia signs and know when to use glucagon.

## Concrete Clinical Example
A 16‑year‑old with type 1 diabetes on insulin pump develops seizures during night‑time hypoglycemia; the sibling administers Baqsimi nasal glucagon promptly, glucose rises to 85 mg/dL within 10 minutes, the patient regains consciousness, and emergency medical services are contacted as a precaution.

**Source:** Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2023, https://doi.org/10.1210/clinem/dgac596